The partnership will leverage the accelerator mass spectrometry (AMS) technology to remove pharmacokinetic uncertainty and offer drug developers early bioavailability data, thus enabling to overcome the limitations of poor pharmacokinetic properties.
The partnership also enables sponsors to make faster decisions in the early stages of development of optimized solid-state forms and formulations.
Xceleron CEO Michael Butler said the company believes that technology can get life-changing drugs to people who need them, sooner and at a lower cost.
"This partnership will help our clients do that by efficiently and cost-effectively answering critical questions earlier," Butler added.